

A New Complex of Diperoxovanadate with 2-(2'-pyridyl)-imidazole: Synthesis, Structure, Interaction and Bioactivity

Y. Pan¹, J. Yan², S. Yang³, X. Li³, S. Cai¹, Z. Chen¹

¹Research Center of Biomedical Engineering and Department of Physics, Xiamen University, Xiamen, Fujian, China, People's Republic of, ²Cancer Research Center, Xiamen University, Xiamen, Fujian, China, People's Republic of, ³Xiamen First Hospital, Xiamen, Fujian, China, People's Republic of

Introduction

Vanadate compounds were reported to be a new kind of powerful insulin mimic and anticancer agents based on their biological response both *in vitro* and *in vivo*. A novel diperoxovanadate complex $\text{NH}_4[\text{OV}(\text{O}_2)_2\{2-(2'\text{-pyridyl})\text{-imidazole}\}]\cdot 4\text{H}_2\text{O}$ was synthesized in aqueous solution under physiological conditions. Its solution structure was characterized by multinuclear (¹H, ¹³C, ¹⁴N, and ⁵¹V) as well as multi-dimensional (DOSY and C-H COSY) NMR techniques in the interaction system of $\text{NH}_4\text{VO}_3/\text{H}_2\text{O}_2/2-(2'\text{-pyridyl})\text{-imidazole}$ at room temperature. It affected the proliferation of tumor cell and normal one in a different manner. In addition, it inhibited the specific activity of ALP (alkaline phosphatase) in gastric cancer cell MGC-803.

Methods

$\text{NH}_4[\text{OV}(\text{O}_2)_2\{2-(2'\text{-Py})\text{-Imi}\}]\cdot 4\text{H}_2\text{O}$ was synthesized according to literature [1]. Anal. Calcd. for $\text{NH}_4[\text{OV}(\text{O}_2)_2(\text{C}_8\text{H}_7\text{N}_3)]\cdot 4\text{H}_2\text{O}$ ($\text{C}_8\text{H}_{19}\text{N}_4\text{O}_9\text{V}$): C, 26.24%; H, 5.23%; N, 15.30%. Found: C, 26.11%; H, 5.05%; N, 15.41%. IR (KBr): $\nu = 3498$ vs ($>\text{N-H}$), 3195 vs, 2916 vs, 2757 vs ($\text{H}_3\text{N}^+\text{-H}$), 1654 m, 1477 s, 1453 m, 1401 m, 1291 w, 1159 m, 974 m, 940 s (V=O), 923 m, 882 m ($\text{O-O}_{\text{peroxo}}$), 863 s ($\text{O-O}_{\text{peroxo}}$), 790 m, 750 m, 707 m, 627 m ($\text{V-O}_{\text{peroxo}}$), 588 s ($\text{V-O}_{\text{peroxo}}$) cm^{-1} . Raman: $\nu = 974$ s (V=O), 884 s ($\text{O-O}_{\text{peroxo}}$), 632 m ($\text{V-O}_{\text{peroxo}}$), 588 m ($\text{V-O}_{\text{peroxo}}$), 494 vs ($\text{V-O}_{\text{peroxo}}$) cm^{-1} . ¹H NMR (D_2O): 7.26 (t, J = 5.9 Hz, 1H), 7.47 (s, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.75 (s, 1H), 7.82 (t, J = 7.7 Hz, 1H), 8.05 (s, 1H) ppm. ¹³C NMR (D_2O): 149.0, 147.4, 145.1, 141.1, 132.9, 127.0, 123.9, 121.2 ppm.

All NMR spectra were recorded on Varian Unity plus 500 spectrometer operating at 500.4 MHz for ¹H, 125.7 MHz for ¹³C, 36.12 MHz for ¹⁴N, and 131.4 MHz for ⁵¹V NMR. The solvent was D_2O . DOSY was recorded using a z-gradient probe, which delivered a maximum gradient strength of 30 G/cm. The DOSY gradient compensated stimulated echo spin lock (DGCSTESL) sequence [2] was used for acquiring DOSY spectra. The crystal structure of the complex was determined at 173 K by single-crystal X-ray diffraction method. Cell proliferation assay was carried out as described in literature [3]. ALP activity assay was applied according to Daniel A. Barrio [4] with some modifications.

Results and Discussion

When 0.25, 0.5, 0.75, 1.0, or 2.0 equivalent of 2-(2'-Py)-Imi was added to the $\text{NH}_4\text{VO}_3/\text{H}_2\text{O}_2$ (1:5 molar ratio) aqueous solution (Fig. 1(a), where bpV refers to the species $[\text{OV}(\text{O}_2)_2(\text{H}_2\text{O})]/[\text{OV}(\text{O}_2)_2(\text{D}_2\text{O})]$), a new single peak appeared at about -784 ppm, as shown in Fig. 1(b)-(f), which was assigned to a new species $[\text{OV}(\text{O}_2)_2\{2-(2'\text{-Py})\text{-Imi}\}]$. Its chemical shift is at the highest field among the known mononuclear diperoxovanadate(V) compounds. The intensity of the new peak increased with the increasing of the quantity of ligand before reaching a maximum.

The ¹H DOSY spectrum of $\text{NH}_4\text{VO}_3/\text{H}_2\text{O}_2/2-(2'\text{-Py})\text{-Imi}$ (1:5:2, 0.2 mol/L vanadate concentration) in solution is shown in Fig. 2. The component with slower diffusion rate marked by broken line was assigned to the newly-formed species, $[\text{OV}(\text{O}_2)_2\{2-(2'\text{-Py})\text{-Imi}\}]$. Another component marked by solid lines was assigned to the free ligand.

The structure unit of the crystal is shown in Fig. 3. The species, $[\text{OV}(\text{O}_2)_2\{2-(2'\text{-Py})\text{-Imi}\}]$, has a distorted pentagonal bipyramidal geometry, as often observed in transition metal peroxo complexes.

Inhibition of $\text{NH}_4[\text{OV}(\text{O}_2)_2\{2-(2'\text{-Py})\text{-Imi}\}]$ on cell proliferation was determined by MTT colorimetric assay. The IC_{50} measurements of $\text{NH}_4[\text{OV}(\text{O}_2)_2\{2-(2'\text{-Py})\text{-Imi}\}]$ were 30.9 μM in L342, 7.35 μM in MGC-803, 6.2 μM in 95D, and 71.5 μM in HEK293. It shows a higher toxicity against some of the cancer cell lines tested, compared with that in the control cell lines HEK293. The effect of $\text{NH}_4[\text{OV}(\text{O}_2)_2\{2-(2'\text{-Py})\text{-Imi}\}]$ on ALP activity was measured by p-NPP colorimetric assay. As shown in Fig. 4, the new complex in the range of 0.1-1000 μM had an inhibitory effect of more than 60% on the ALP activity of cell extracted from gastric cancer cell line MGC-803.

Acknowledgments

This work was supported by Key Project of Health and Science and Technology of Xiamen, and Project Wkj2005-2-019 supported by Science Research Foundation of Ministry of Health & United Fujian Provincial Health and Education Project for Tackling the Key Research, P. R. China.

References

- [1] Yu XY, et al. J. Inorg. Biochem. 99 (2005) 1945-1951.
- [2] Pelta MD, et al. Magn. Reson. Chem. 36 (1998) 706-714.
- [3] Rumora L, et al. Biochem. Bioph. Res. C 300 (2003) 877-883.
- [4] Barrio DA, et al. J. Biol. Inorg. Chem. 8 (2003) 459-468.




Fig. 1. ⁵¹V spectra of the $\text{NH}_4\text{VO}_3/\text{H}_2\text{O}_2/2-(2'\text{-Py})\text{-Imi}$ aqueous solution with 0.2 mol/L the total concentration of vanadate species.




Fig. 3. Structure of $\text{NH}_4[\text{OV}(\text{O}_2)_2\{2-(2'\text{-Py})\text{-Imi}\}]\cdot 4\text{H}_2\text{O}$.




Fig. 4. Effects of new complex on ALP activities extracted from gastric cancer cell MGC-803. Cell extract added to the glycine buffer with 5mM p-NPP alone (basal) or with different concentrations of the new complex.